120 related articles for article (PubMed ID: 10731049)
61. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
62. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
63. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
64. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727
[TBL] [Abstract][Full Text] [Related]
65. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
[TBL] [Abstract][Full Text] [Related]
66. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin.
Giacomelli S; Gallo D; Apollonio P; Ferlini C; Distefano M; Morazzoni P; Riva A; Bombardelli E; Mancuso S; Scambia G
Life Sci; 2002 Feb; 70(12):1447-59. PubMed ID: 11883719
[TBL] [Abstract][Full Text] [Related]
67. Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm.
Arafa HM; Abdel-Hamid MA; El-Khouly AA; Elmazar MM; Osman AM
Toxicology; 2006 May; 222(1-2):103-13. PubMed ID: 16567030
[TBL] [Abstract][Full Text] [Related]
68. Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice.
Gong C; Qian L; Yang H; Ji LL; Wei H; Zhou WB; Qi C; Wang CH
BMC Complement Altern Med; 2015 Aug; 15():283. PubMed ID: 26283082
[TBL] [Abstract][Full Text] [Related]
69. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
70. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
71. Lung cancer targeted therapy: Folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin.
Tan S; Wang G
Biomed Pharmacother; 2018 Jun; 102():55-63. PubMed ID: 29549729
[TBL] [Abstract][Full Text] [Related]
72. Acute toxicity study of cisplatin loaded long-circulating and pH-sensitive liposomes administered in mice.
Leite EA; Lana AM; Junior AD; Coelho LG; De Oliveira MC
J Biomed Nanotechnol; 2012 Apr; 8(2):229-39. PubMed ID: 22515074
[TBL] [Abstract][Full Text] [Related]
73. Intracellular accumulation of thallium as a marker of cisplatin cytotoxicity in nonsmall cell lung carcinoma: an application of inductively coupled plasma mass spectrometry.
Hanada T; Isobe H; Saito T; Ogura S; Takekawa H; Yamazaki K; Tokuchi Y; Kawakami Y
Cancer; 1998 Sep; 83(5):930-5. PubMed ID: 9731897
[TBL] [Abstract][Full Text] [Related]
74. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
Li Y; Chen N; Palmisano M; Zhou S
Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
[TBL] [Abstract][Full Text] [Related]
75. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
[TBL] [Abstract][Full Text] [Related]
76. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
77. Role of formulation vehicles in taxane pharmacology.
van Zuylen L; Verweij J; Sparreboom A
Invest New Drugs; 2001 May; 19(2):125-41. PubMed ID: 11392447
[TBL] [Abstract][Full Text] [Related]
78. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
79. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
Kondo A; Maeta M; Oka A; Tsujitani S; Ikeguchi M; Kaibara N
Br J Cancer; 1996 May; 73(10):1166-70. PubMed ID: 8630273
[TBL] [Abstract][Full Text] [Related]
80. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.
Dickey DT; Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Sep; 314(3):1052-8. PubMed ID: 15951398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
